At CSL Behring AG, I was first responsible the first two years for the initiation, planning, execution and monitoring of global and local R&D projects predominantly around life cycle management of drug products, ensuring detailed, realistic and accurate planning in regard to timelines and resources.
I then moved to the Strategic Projet Portfolio and Operational Excellence Department and I was responsible for the execution of „Genesis II“ project, which consisted in the upgrade of a manufacturing bulk facility, the adaptation of an existing filing line, the implementation of a new lyophilisation facility,
the upgrade of visual inspection and the implementation of packaging & labelling for the launch of the new commercial product called “CSL112”, which is an active Apolipoprotein A-I, purified from human plasma. In this project I assembled and managed a cross-functional project team of more than 30 team
members for a total investment of 90 mio USD.
SWITCH edu-ID
Verwaltung
